Royal Biologics Announces Commerical Launch of Derm-Maxx(TM) and Newly Formed Wound Care Division
HACKENSACK, NJ / ACCESSWIRE / November 28, 2023 / Royal Biologics, Inc., a company specializing in Advanced Cellular & Autologous...
Month: November 2023
Canopus Biopharma Inc. DBA Blue Heaven Coffee Inc. Announces Canada-Wide Interprovincial Deployment of Newest Generation Artificial Intelligence (AI) Powered Digital Vending Machine Units
LAS VEGAS, NV / ACCESSWIRE / November 28, 2023 / Canopus Biopharma Inc. (OTC PINK:CBIA) DBA Blue Heaven Coffee Inc....
NLS Pharmaceutics Announces Election of Additional Board Members
Professor Claudio L. A. Bassetti, MD, is the Chair, Neurology Department, Inselspital, Bern University Hospital and Dean, Medical Faculty, University...
Infinx Healthcare Named as Representative Vendor in Gartner’s Market Guide for Intelligent Prior Authorization, U.S. Healthcare Organizations
Research firm Gartner recognizes Infinx Healthcare in their first ever Market Guide for Intelligent Prior Authorization for U.S. healthcare organizations.NEW...
Nutriband Inc. Expands its AI Kinesiology Tape Portfolio with the Launch of AI Tape Heating and Cooling
ORLANDO, FL / ACCESSWIRE / November 28, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today...
The Phase 1a/1b Human Clinical Trial of NV-CoV-2, the Company’s Broad-Spectrum Antiviral Drug, Has Successfully Completed the First Part (Phase 1a), Reports NanoViricides
SHELTON, CT / ACCESSWIRE / November 28, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development...
Zomedica to Present at Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference
ANN ARBOR, MI / ACCESSWIRE / November 28, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary...
SciSparc Adopts Limited Duration Shareholder Rights Plan
TEL AVIV, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical...
Baptist Health Lexington Enhances 20-Year Leadership in Pioneering Advanced Robotic Technology for Heart Disease Patients
LEXINGTON, Ky. and ST. LOUIS, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for...
Kineta to Host KOL Event to Review New Data from VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors on December 5, 2023
SEATTLE, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of...
Alpha Tau Announces Highly Promising Interim Results from Safety and Feasibility Trial of Alpha DaRT Treatment of Advanced Pancreatic Cancer
- Interim data read-out of the first five treated patients demonstrated successful delivery in all five cases, as well as...
Cerevance Announces Presentation at the 34th International Symposium on ALS/MND
BOSTON, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing novel precision therapeutics for central nervous system...
Femasys Inc. Completes Enrollment of FemaSeed Pivotal Trial in Support of Commercial Launch
- Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 -...
Vaxcyte Appoints Jacks Lee to Board of Directors
SAN CARLOS, Calif., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines...
Milestone Announces Agreement with Bioline Supply to Distribute the CompuFlo® Epidural System and Related Disposables Across Spain
ROSELAND, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments...
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
Proof of Concept – Evaxion’s AI-Immunology™ platform demonstrates success in designing precision cancer vaccines in hematological cancers by targeting a...
SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment
The pre- clinical trial conducted using the combined treatment of SciSparc's proprietary CannAmide™ and Clearmind Medicine's MEAI molecule TEL AVIV,...
Clearmind Medicine Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic- Based Treatment
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite...
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer
Cohort 9 Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or...
Sol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610
Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with...